福瑞医科 (300049.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	1.6B	1.6B	1.3B	1.2B	1.0B
Cost of Revenue	413.0M	399.4M	349.0M	291.4M	267.7M
Gross Profit	1.2B	1.2B	1000.0M	862.3M	741.1M
Operating Expenses
R&D Expense	120.5M	111.2M	99.5M	82.5M	70.8M
SG&A Expense	—	—	—	—	—
General & Admin Expense	282.7M	284.9M	240.6M	206.1M	193.9M
Selling & Marketing Expense	395.2M	390.2M	343.6M	321.4M	280.6M
Other Expenses	—	—	—	—	—
Total Operating Expenses	810.3M	813.9M	668.4M	614.4M	544.4M
Cost and Expenses	1.2B	1.2B	1.0B	905.8M	812.1M
Operating Income (EBIT)	384.4M	368.3M	277.9M	253.1M	192.7M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	363.5M	350.6M	270.6M	235.4M	191.6M
Income Tax Expense	94.7M	92.1M	74.7M	58.3M	46.2M
Bottom Line
Net Income	157.2M	154.1M	113.3M	101.6M	97.9M
Earnings from Cont. Ops	268.9M	258.4M	195.9M	177.1M	145.4M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	157.2M	154.1M	113.3M	101.6M	97.9M
Per Share
Basic EPS	CN¥0.60	CN¥0.58	CN¥0.43	CN¥0.39	CN¥0.37
Diluted EPS	CN¥0.60	CN¥0.58	CN¥0.43	CN¥0.39	CN¥0.37
Revenue Per Share	CN¥6.13	CN¥6.01	CN¥5.12	CN¥4.39	CN¥3.83
Shares
Basic Shares Outstanding	265.0M	265.7M	263.5M	263.1M	263.1M
Diluted Shares Outstanding	265.0M	265.7M	263.5M	263.1M	263.1M
Profitability Metrics
EBITDA	—	450.5M	354.1M	329.6M	254.6M
D&A	—	82.2M	76.2M	76.5M	61.9M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026